This uncertainty highlights the need for more standardized research protocols using a clearer AMS definition and a more detailed reporting of important confounding factors of AMS.

Tinh-Hai Collet, MD
David Meier, MD
Claudio Sartori, MD

Author Affiliations: Service of Endocrinology, Diabetes, and Metabolism, Lausanne University Hospital, Lausanne, Switzerland (Collet); Service of Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland (Meier, Sartori).

Corresponding Author: Tinh-Hai Collet, MD, Service of Endocrinology, Diabetes, and Metabolism, Lausanne University Hospital, Bugnon 46, 1011 Lausanne, Switzerland (tinh-hai.collet@chuv.ch).

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Collet reported receiving grants from the Swiss National Science Foundation. No other disclosures were reported.


CORRECTION

Author Names Omitted: In the article entitled "Effect of Haloperidol on Survival Among Critically Ill Adults With a High Risk of Delirium: The REDUCE Randomized Clinical Trial" published in the February 20, 2018, issue of JAMA, several authors’ names, affiliations, and contributions were omitted. This article was corrected online.


Incorrect Age Range: In the Editorial entitled "Screening for Prostate Cancer: Is the Third Trial the Charm?"1 published in the March 6, 2018, issue of JAMA, an incorrect age range was reported twice. In the first paragraph, the third sentence should be "In this cluster randomized trial, 573 primary care practices in the United Kingdom offered men aged 50 to 69 years a single PSA screening test or usual care." In the fifth paragraph, the second sentence should be "Based on the CAP results, an offer of a single PSA screen in a population of men aged 50 to 69 years is ineffective, and given the higher risk of a prostate cancer diagnosis this approach engenders, likely does more harm than good." This article was corrected online.

Incorrect Data Reported: In the Viewpoint entitled “Hip and Knee Replacements: A Neglected Potential Savings Opportunity,” published in the March 13, 2018, issue, incorrect data were reported. The sentence in the second paragraph should have read as follows: “In 2017, the Organisation for Economic Cooperation and Development reported that hip replacements in the United States increased 22% (from 167 to 204 per 100,000) and knee replacements increased 22% (from 185 to 226 per 100,000).” This article was corrected online.


Guidelines for Letters

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment and the ICMJE Form for Disclosure of Potential Conflicts of Interest are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editor: Jody W. Zylke, MD, Deputy Editor.